G R O U P S T A T S
When it comes to advanced scientific degrees, we field the largest biotechnology group in New England 36 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.
Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies,and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.
Our expertise is broadand deep, covering areas from antibodies to transgenic technologiesand everything inbetween. We also call on members of our other practice groups includingChemical & Materials Technologies and Pharmaceuticalwhen their specialized expertise will benefit a clients project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.
Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.
Representative clients:
For older news items, please go to News & Events.
Laura Vogel presents at ACI Conference
Wolf Greenfield and Client Cold Spring Harbor Laboratory Prevail in 4 IPRs
A.J. Tibbetts and Ed Walsh Present at BBA's 16th Annual Intellectual Property Year in Review
Wolf Greenfield Welcomes Counsel Laura Vogel
Wolf Greenfield and Client BTG Reach Favorable Outcome in IPR for CroFab Rattlesnake Antivenom Patent
LMG Life Sciences Recognizes Wolf Greenfield
Wolf Greenfield Welcomes Shareholder Jeffrey Hsi, Expert in Technology Commercialization
Wolf Greenfield Recognized in 2016 "Best Law Firms" Rankings
23 Wolf Greenfield Attorneys Named to 2015 Massachusetts Super Lawyers List
24 Wolf Greenfield Lawyers Named to 2015 Massachusetts Rising Stars List
Oona Johnstone interviewed by ASHG for Featured Chat Fridays
Managing IP Magazine Recognizes Wolf Greenfield
Favorable Outcome for BTG in Snake Antivenom ITC Investigation
Chelsea Loughran talks about CRISPR in Xconomy
20 Wolf Greenfield Lawyers Named to 2014 Massachusetts Rising Stars List
22 Wolf Greenfield Attorneys Named to 2014 Massachusetts Super Lawyers List
Pat Granahan comments on the battle to own CRISPR
Pat Granahan and Chelsea Loughran quoted on CRISPR-Cas in Nature Biotechnology
Patrick Waller interviewed by Radio Entrepreneurs
GenomeWeb quotes Chelsea Loughran on IP landscape surrounding CRISPR-Cas9
Wolf Greenfield Recognized by Managing IP Magazine
Chelsea Loughran quoted in The Scientist on first awarded CRISPR-Cas9 patent
Chelsea Loughran quoted in MIT Tech Review on first awarded patent for engineered CRISPR-Cas9 system
Doug Wolf featured as the Entrepreneur.com expert for the month of March
G R O U P S T A T S
When it comes to advanced scientific degrees, we field the largest biotechnology group in New England 36 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.
Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies,and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.
Our expertise is broadand deep, covering areas from antibodies to transgenic technologiesand everything inbetween. We also call on members of our other practice groups includingChemical & Materials Technologies and Pharmaceuticalwhen their specialized expertise will benefit a clients project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.
Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.
Representative clients:
For older news items, please go to News & Events.
Laura Vogel presents at ACI Conference
Wolf Greenfield and Client Cold Spring Harbor Laboratory Prevail in 4 IPRs
A.J. Tibbetts and Ed Walsh Present at BBA's 16th Annual Intellectual Property Year in Review
Wolf Greenfield Welcomes Counsel Laura Vogel
Wolf Greenfield and Client BTG Reach Favorable Outcome in IPR for CroFab Rattlesnake Antivenom Patent
LMG Life Sciences Recognizes Wolf Greenfield
Wolf Greenfield Welcomes Shareholder Jeffrey Hsi, Expert in Technology Commercialization
Wolf Greenfield Recognized in 2016 "Best Law Firms" Rankings
23 Wolf Greenfield Attorneys Named to 2015 Massachusetts Super Lawyers List
24 Wolf Greenfield Lawyers Named to 2015 Massachusetts Rising Stars List
Oona Johnstone interviewed by ASHG for Featured Chat Fridays
Managing IP Magazine Recognizes Wolf Greenfield
Favorable Outcome for BTG in Snake Antivenom ITC Investigation
Chelsea Loughran talks about CRISPR in Xconomy
20 Wolf Greenfield Lawyers Named to 2014 Massachusetts Rising Stars List
22 Wolf Greenfield Attorneys Named to 2014 Massachusetts Super Lawyers List
Pat Granahan comments on the battle to own CRISPR
Pat Granahan and Chelsea Loughran quoted on CRISPR-Cas in Nature Biotechnology
Patrick Waller interviewed by Radio Entrepreneurs
GenomeWeb quotes Chelsea Loughran on IP landscape surrounding CRISPR-Cas9
Wolf Greenfield Recognized by Managing IP Magazine
Chelsea Loughran quoted in The Scientist on first awarded CRISPR-Cas9 patent
Chelsea Loughran quoted in MIT Tech Review on first awarded patent for engineered CRISPR-Cas9 system
Doug Wolf featured as the Entrepreneur.com expert for the month of March
Some areas of expertise
Read more:
Biotechnology | Wolf Greenfield
- Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future - Analytics Insight - February 24th, 2025
- The Security Implications of Developments in Biotechnology - International Institute for Strategic Studies - February 24th, 2025
- Biotechnology Permits and Notifications - USDA APHIS - February 24th, 2025
- Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage - Nature.com - February 24th, 2025
- Internal cap-initiated translation for efficient protein production from circular mRNA - Nature.com - February 24th, 2025
- MIT class takes students on a grand tour of the interdisciplinary world of biotech - MIT News - February 24th, 2025
- BioTech Breakthrough Awards BostonGene With Cancer Immunology Solution of the Year - Business Wire - February 24th, 2025
- Biodiversity to Bioeconomy - PIB - February 24th, 2025
- Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment... - February 24th, 2025
- Biofach 2025: Biosan Biotechnology CEO talks popular mushroom blends and wellness benefits - Nutrition Insight - February 24th, 2025
- Pushing the boundaries of biotechnology - UC Santa Cruz - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims & More: Daily Recap (1/26/25) - WDW News Today - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims in EPCOT - WDW News Today - January 27th, 2025
- Biotechnology led to dramatic innovations in agriculture and human health in 2024 - Genetic Literacy Project - January 27th, 2025
- Cultured algae and biotechnology are ingredients to the 'Gelato of the future' - STIRworld - January 27th, 2025
- New U.S. Export Controls Seek to Prevent China From Weaponizing Biotech - Foundation for Defense of Democracies - January 27th, 2025
- Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? - Nature.com - January 27th, 2025
- Nuevocor Welcomes Andreas Wallnfer as Chairman of the Board of Directors - Kilgore News Herald - January 27th, 2025
- Creating and sustaining university biotech spin-outs - PMLiVE - January 27th, 2025
- IMTECH celebrates 41st foundation day with focus on BioE3 policy and biotechnology innovations - The Times of India - January 27th, 2025
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023